- Home
- REFR vs SLS Comparison
REFR vs SLS Comparison
Compare REFR & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- SLS
- Stock Information
- Founded
- REFR 1965
- SLS 2012
- Country
- REFR United States
- SLS United States
- Employees
- REFR N/A
- SLS N/A
- Industry
- REFR Multi-Sector Companies
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- REFR Miscellaneous
- SLS Health Care
- Exchange
- REFR Nasdaq
- SLS Nasdaq
- Market Cap
- REFR 67.4M
- SLS 75.3M
- IPO Year
- REFR N/A
- SLS N/A
- Fundamental
- Price
- REFR $1.71
- SLS $0.88
- Analyst Decision
- REFR
- SLS
- Analyst Count
- REFR 0
- SLS 0
- Target Price
- REFR N/A
- SLS N/A
- AVG Volume (30 Days)
- REFR 25.1K
- SLS 1.6M
- Earning Date
- REFR 11-07-2024
- SLS 11-13-2024
- Dividend Yield
- REFR N/A
- SLS N/A
- EPS Growth
- REFR N/A
- SLS N/A
- EPS
- REFR N/A
- SLS N/A
- Revenue
- REFR $1,469,616.00
- SLS N/A
- Revenue This Year
- REFR N/A
- SLS N/A
- Revenue Next Year
- REFR N/A
- SLS N/A
- P/E Ratio
- REFR N/A
- SLS N/A
- Revenue Growth
- REFR 102.07
- SLS N/A
- 52 Week Low
- REFR $0.91
- SLS $0.50
- 52 Week High
- REFR $2.41
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- REFR 26.45
- SLS 30.01
- Support Level
- REFR $1.68
- SLS $0.86
- Resistance Level
- REFR $1.95
- SLS $0.98
- Average True Range (ATR)
- REFR 0.09
- SLS 0.11
- MACD
- REFR -0.01
- SLS -0.02
- Stochastic Oscillator
- REFR 8.60
- SLS 21.74
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. Its revenue source comes from the licensing of technology.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.